Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy
Posted inCardiology Diabetes & Endocrinology news

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy

The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile of dual GIP/GLP-1 agonism compared to established standards of care.
Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial
Posted inCardiology news Psychiatry

Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial

A 3‑arm randomized trial in 524 adults with congenital heart disease found a 4‑week tailored digital emotion‑regulation program produced moderate improvements in emotion regulation and multiple psychosocial outcomes versus usual care; a general program showed delayed, smaller benefits.
Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies
Posted inCardiology Clinical Updates General Surgery news

Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies

This review synthesizes evidence demonstrating that 4-factor prothrombin complex concentrate (4F-PCC) offers superior hemostatic efficacy and safety compared to frozen plasma in managing coagulopathic bleeding during cardiac surgery, supported by the recent FARES-II trial and corroborating clinical research.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial
Posted inCardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial

In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, providing no net clinical benefit versus anticoagulant monotherapy.